clinical trial · NCT07131514
HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Pancreatic CancerHRS-4642+AG +Adebrelimab
brief summary
To evaluate the safety and efficacy of HRS-4642 in Combination With AG and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
started
Aug 25, 2025
primary completion
Jun 1, 2027
completion
Dec 1, 2027
last updated
Jan 2, 2026
detailed description
This study is an open, single center, exploratory clinical trial aimed at evaluating the safety and efficacy of HRS-4642 in combination with gemcitabine and albumin-bound paclitaxel and Adebrelimab for neoadjuvant and adjuvant treatment of pancreatic cancer
official title
An Exploratory Clinical Study of HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol